Economic Evaluation Seminar Thursday 15th October 11.15am - 12.15pm #healtheconomics
@healtheconall.bsky.social
@healtheconall.bsky.socialEconomic Evaluation Seminar Thursday 15th October 11.15am - 12.15pm #healtheconomics
@healtheconall.bsky.socialCHE Annual Report 2025 #healtheconomics
@healtheconall.bsky.socialDPhil Opportunity #healtheconomics
@abangelabs.bsky.socialSix asthma studies show what a strong local value case for combination reliever access needs. https://www.mattheneus.com/editorial/asthma-ics-formoterol-cost-effectiveness-local-value-file-2026-10-08 #HTA #HealthEconomics #RWE
@abangelabs.bsky.socialA zero-event study can leave exploratory dressing comparisons unresolved. See how unanchored MAIC frames the residual uncertainty.
https://www.mattheneus.com/editorial/sacral-dressing-unanchored-maic-residual-differences-2026-10-07
#HTA #MAIC #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialGermany’s G-BA leaves Zynyz’s benefit magnitude open after a single-arm Merkel cell carcinoma study. https://www.mattheneus.com/editorial/g-ba-zynyz-mcc-benefit-extent-single-arm-podium201-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs
@abangelabs.bsky.socialEU selects its first two medical devices for joint clinical assessment. https://www.mattheneus.com/editorial/european-commission-first-medical-device-jca-sapien-m3-highlife-mitral-valves-2026-10-06 #HTA #RegulatoryAffairs #HealthEconomics
@abangelabs.bsky.socialWHO updates pre-eclampsia evidence across magnesium sulfate, aspirin and calcium, sharpening priorities for maternal health. https://www.mattheneus.com/editorial/who-pre-eclampsia-fact-sheet-magnesium-aspirin-calcium-evidence-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics
@healtheconall.bsky.socialNew UCL HEART short courses – online and in person #healtheconomics
@abangelabs.bsky.socialDaily sedation interruption may shorten ventilation and lower mortality, according to a Cochrane review. https://www.mattheneus.com/editorial/cochrane-daily-sedation-interruption-ventilation-mortality-randomised-review-2026-10-07 #HTA #EvidenceSynthesis #HealthEconomics
@ajhejournal.bsky.socialPayment policy can reshape the health care workforce. Just accepted! A federal mandate requiring Medicaid reimbursement of nurse-midwives increased midwife-attended births by 69% and expanded care into previously unserved areas. www.journals.uchicago.edu/doi/10.1086/744122
#HealthEconomics #Medicaid
@abangelabs.bsky.socialThe UK’s 44-point healthcare AI plan makes evidence strategy central: staged access will depend on credible economic appraisal. #HTA #HealthEconomics #RegulatoryAffairs https://www.mattheneus.com/editorial/uk-healthcare-artificial-intelligence-staged-access-economic-appraisal-2026-10-06
@ihea.bsky.social🤝 Upcoming Networking & Mentoring Event
📅 October 21, 2026
🕛 12:00 – 1:00 PM UTC + 0
🔗 Register for the session: www.healtheconomics.org/event/networ...
Submit your abstract here: docs.google.com/spreadsheets...
#Networking #Mentoring #HealthEconomics #HealthPolicy #HealthResearch
@abangelabs.bsky.socialAHRQ is offering 1.8 million for research on healthcare competition and patient choice, putting evidence behind market reform. https://www.mattheneus.com/editorial/ahrq-healthcare-choice-competition-challenge-market-reform-evidence-2026-10-06 #HTA #HealthEconomics #RWE
@abangelabs.bsky.socialTwo-stage economic evidence reviews can reduce HTA rework. https://www.mattheneus.com/editorial/pharmacoeconomics-systematic-health-economic-evaluation-reviews-two-stage-hta-2026-10-06 #HTA #HealthEconomics #Pharma
@abangelabs.bsky.socialRisk misclassification can reshape the value case for risk-stratified breast screening. https://www.mattheneus.com/editorial/risk-stratified-breast-screening-misclassification-capacity-cost-effectiveness-2026-10-01 #HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialA €607 annual price threshold sharpens the value case for empagliflozin after myocardial infarction. https://www.mattheneus.com/editorial/pubmed-empagliflozin-post-mi-heart-failure-risk-price-threshold-2026-10-05 #HTA #HealthEconomics #Pharma
@abangelabs.bsky.socialGermany’s Lynkuet assessment shows how comparative follow-up duration can determine added-benefit conclusions. https://www.mattheneus.com/editorial/g-ba-elinzanetant-breast-cancer-endocrine-vasomotor-oasis4-duration-gap-2026-10-01 #HTA #Pharma #HealthEconomics
@abangelabs.bsky.socialIntelligent-knife evidence now needs to connect diagnostic accuracy with surgical and patient outcomes. https://www.mattheneus.com/editorial/pubmed-intelligent-knife-cancer-surgery-diagnostic-outcomes-evidence-gap-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics
@zachtempleton.bsky.socialNew paper out in Medical Care: What are the effects of medicine specialty consults on outcomes among general medicine patients?